200 300 400 500 600 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg 8 74 79 92 100 0 20 40 60 80 100 0 1 4 8 12 16 20 24 38 38 33 25 21 N values Pooled KSI-101 Patients, % Weeks 55 68 91 92 100 0 20 40 60 80 100 0 1 4 8 12 16 20 24 Patients, % Weeks Proportion of patients achieving absence of IRF b Proportion of patients achieving absence of SRF b The APEX study is ongoing. Final results may be different due to additional data collection or data cleaning. a Includes patients in the per protocol set that completed the Week 12 visit and met all the eligibility criteria. Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). b Includes patients in the per protocol set that meet all the eligibility criteria. Excludes one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). Includes all data available by the 14-Jul-25 reporting date. 9 38 38 33 25 21 N values Pooled KSI-101 APEX KSI-101 in MESI – A single dose of KSI-101 results in the majority of patients achieving dryness. Over 90% of patients achieve dryness by Week 8 Mean CST (μm) Observed OCT CST over time a Weeks 2.5 mg 13 13 13 13 13 5 mg 13 13 13 13 13 10 mg 13 13 13 13 13 Dryness (CST <325) -216 -240 -165 Sample Size Mean Change Dose Level